ArticleNature cell biology2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Abstract read
In one paragraph
Article in Nature cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 2 pooled it
14.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
252 citing papers in PubMed, 2 syntheses or guidelines pooled it, 411 citations in OpenAlex.
- A comprehensive overview of the molecular features and therapeutic targets in BRAFClinical and translational medicine · 2024Pooled it
- Dichotomous role of Shp2 for naïve and primed pluripotency maintenance in embryonic stem cells.Stem cell research & therapy · 2022Pooled it
- Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Nature communications · 2026Trial
- Insulin resistance in the 21st century: new takes on an old problem-2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetologia · 2026Review
- Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026Review
- Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.Investigational new drugs · 2026Article
- Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms.bioRxiv : the preprint server for biology · 2026Article
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer.Scientific reports · 2026Article
- New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer.Cancer science · 2026Review
- Pancreatic Cancer: Translating Tumor Biology into Actionability.Cancer discovery · 2026Review
- Precision Targeting ofInternational journal of molecular sciences · 2026Review
- SHP2 as a pivotal modulator of the tumor microenvironment in gastrointestinal cancers: from mechanisms to targeted therapies.Journal of translational medicine · 2026Review
- Probing 3-Amino-2H-Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2.ChemMedChem · 2026Article
- Posttranslational modifications remodel proteome-wide ligandability.Nature chemical biology · 2026Article
- Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Nature communications · 2026Article
- Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer.Journal of pharmaceutical analysis · 2026Article
- KRAS Inhibition in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2026Review
- RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Cancer research · 2026Article
- Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.Molecular cancer research : MCR · 2026Article
192 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Robert J NicholsDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Franziska HaderkDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Carlos StahlhutDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Christopher J SchulzeDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Golzar HemmatiDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
David WildesDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Christos TzitzilonisDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Kasia MordecDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Abby MarquezDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Jason RomeroDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Tientien HsiehDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Aubhishek ZamanDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Victor OlivasDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Caroline McCoachDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Collin M BlakelyDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Zhengping WangDepartment of Development Sciences, Revolution Medicines, Inc., Redwood City, CA, USA.
Gert KissDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Elena S KoltunDepartment of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
Adrian L GillDepartment of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
Mallika SinghDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Mark A GoldsmithDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Jacqueline A M SmithDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA. jan@revolutionmedicines.com.ORCID http://orcid.org/0000-0001-5028-8725
Trever G BivonaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.ORCID http://orcid.org/0000-0001-5734-4128
Revolution Medicines (United States) · USUniversity of California, San Francisco · US
Funding
Project 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI KEVIN M. SHANNON · 2015 to 2026
$26.9MUCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9MThe Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2MCharacterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7MRational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentR01CA169338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2013 to 2023
$3.4MDiscovery of Rational Companion Therapeutic Targets to Optimize Cancer TreatmentDP2CA174497 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2012 to 2012
$2.3MOptimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8MDoris Duke Charitable Foundation 2018110NCI NIH HHS DP2 CA174497NCI NIH HHS R01 CA169338NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS U01 CA217882NCI NIH HHS U54 CA196519NCI NIH HHS U54 CA224081
Abstract
Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAF
Indexed as
MutationAnimalsAntineoplastic AgentsBiomarkers, TumorCell Line, TumorEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesGenetic Predisposition to DiseaseGuanosine TriphosphateHEK293 CellsHumansMice, Inbred BALB CMice, NudeMitogen-Activated Protein Kinase KinasesNeoplasmsNeurofibromin 1Antineoplastic AgentsBiomarkers, TumorBRAF protein, humanEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesGuanosine TriphosphateKRAS protein, humanMitogen-Activated Protein Kinase KinasesNeurofibromin 1NF1 protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)raf KinasesSOS1 Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.